Drug Profile
OLX 401A
Alternative Names: OLX-401ALatest Information Update: 10 May 2022
Price :
$50
*
At a glance
- Originator OliX Pharmaceuticals
- Class Analgesics; Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Neuropathic pain
Most Recent Events
- 10 May 2022 Olix Pharmaceuticals has patent protection for asiRNA technology in Korea, Europe, Japan, Australia and China prior to May 2022 (Olix Pharmaceuticals pipeline, May 2022)
- 10 May 2022 Olix Pharmaceuticals has patent protection for cp-asiRNA technology in South Korea, USA, Europe, Japan and China prior to May 2022 (Olix Pharmaceuticals website, May 2022)
- 04 May 2022 Preclinical trials in Neuropathic pain in South Korea (Intrathecal)